Clinical Trial Update: Impact on Reducing the Incidence of Low Serum Calcium by Providing Educational Materials on the Need to Take Daily Supplemental Calcium and Vitamin D to Patients With Paget's Disease Treated With Reclast® [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating whether providing educational materials about daily calcium and vitamin D reduces the incidence of hypocalcemia in patients with Paget'…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypocalcemia
• Paget Disease of the Bone

Drugs mentioned

• RECLAST (ZOLEDRONIC ACID)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Paget's Disease of the Bone, Hypocalcemia | Phase 4 | Status: COMPLETED | Results posted: 2014-03-03